(RTTNews) - Wednesday. Eli Lilly and Company (LLY) reported detailed results from the Phase 3 ACHIEVE-4 trial showing that Foundayo (orforglipron) demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in adults with type 2 diabetes and obesity or ov
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.